Comparative effectiveness of extended release naltrexone and sublingual buprenorphine for treatment of opioid use disorder among Medicaid patients
View ORCID ProfileRachael K. Ross, View ORCID ProfileEdward V. Nunes, Mark Olfson, Matisyahu Shulman, Noa Krawczyk, Elizabeth A. Stuart, Kara E. Rudolph
doi: https://doi.org/10.1101/2024.01.24.24301555
Rachael K. Ross
1Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY
Edward V. Nunes
2Department of Psychiatry, Columbia University Irving Medical Center
3New York State Psychiatric Institute, New York, NY
Mark Olfson
1Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY
2Department of Psychiatry, Columbia University Irving Medical Center
3New York State Psychiatric Institute, New York, NY
Matisyahu Shulman
2Department of Psychiatry, Columbia University Irving Medical Center
3New York State Psychiatric Institute, New York, NY
Noa Krawczyk
4Department of Population Health, New York University, New York, NY
Elizabeth A. Stuart
5Department of Biostatistics, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD
Kara E. Rudolph
1Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY
Data Availability
Research data are not shared. The data that support the findings of this study are available from the Research Data Assistance Center. Restrictions apply to the availability of these data, which were used under license for this study. All code and data definitions are available at https://github.com/CI-NYC.
Posted April 01, 2024.
Comparative effectiveness of extended release naltrexone and sublingual buprenorphine for treatment of opioid use disorder among Medicaid patients
Rachael K. Ross, Edward V. Nunes, Mark Olfson, Matisyahu Shulman, Noa Krawczyk, Elizabeth A. Stuart, Kara E. Rudolph
medRxiv 2024.01.24.24301555; doi: https://doi.org/10.1101/2024.01.24.24301555
Comparative effectiveness of extended release naltrexone and sublingual buprenorphine for treatment of opioid use disorder among Medicaid patients
Rachael K. Ross, Edward V. Nunes, Mark Olfson, Matisyahu Shulman, Noa Krawczyk, Elizabeth A. Stuart, Kara E. Rudolph
medRxiv 2024.01.24.24301555; doi: https://doi.org/10.1101/2024.01.24.24301555
Subject Area
Subject Areas
- Addiction Medicine (325)
- Allergy and Immunology (635)
- Anesthesia (168)
- Cardiovascular Medicine (2418)
- Dermatology (208)
- Emergency Medicine (382)
- Epidemiology (11831)
- Forensic Medicine (10)
- Gastroenterology (705)
- Genetic and Genomic Medicine (3792)
- Geriatric Medicine (353)
- Health Economics (641)
- Health Informatics (2425)
- Health Policy (943)
- Hematology (344)
- HIV/AIDS (795)
- Medical Education (372)
- Medical Ethics (105)
- Nephrology (404)
- Neurology (3547)
- Nursing (200)
- Nutrition (531)
- Oncology (1844)
- Ophthalmology (541)
- Orthopedics (223)
- Otolaryngology (287)
- Pain Medicine (234)
- Palliative Medicine (68)
- Pathology (450)
- Pediatrics (1045)
- Primary Care Research (425)
- Public and Global Health (6212)
- Radiology and Imaging (1301)
- Respiratory Medicine (838)
- Rheumatology (381)
- Sports Medicine (327)
- Surgery (409)
- Toxicology (51)
- Transplantation (174)
- Urology (148)